<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897923</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000529768</org_study_id>
    <secondary_id>UIHC-LS0383</secondary_id>
    <secondary_id>MAYO-IRB-1414-03</secondary_id>
    <nct_id>NCT00897923</nct_id>
  </id_info>
  <brief_title>Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma
      tumors may help doctors predict how well patients will respond to treatment, and may help the
      study of cancer in the future.

      PURPOSE: This study is measuring radiolabeled white blood cells in patients with
      non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the number of indium In 111-labeled peripheral blood mononuclear cells (PBMCs)
           and indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into lymphoma
           tumors prior to therapy in patients with non-Hodgkin's lymphoma.

        -  Compare the number of PBMC and PMNL trafficking prior to vs after therapy in these
           patients.

        -  Compare, preliminarily, the number of in vivo baseline (i.e., pre-therapy) trafficking
           of PBMCs vs PMNLs in these patients.

        -  Gather important data regarding the inter- and intra-patient variability of effector
           cell trafficking into these tumors.

        -  Assess the relationship between response at 8-12 weeks and the magnitude of baseline
           effector cell trafficking or the magnitude of post-rituximab effector cell trafficking
           in these patients.

      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups.

        -  Group I: Patients receive autologous indium In 111 (^111In)-labeled peripheral blood
           mononuclear cells on day 0.

        -  Group II: Patients receive autologous ^111In-labeled polymorphonuclear leukocytes on day
           0.

      In both groups, patients undergo blood collection on day 0. Patients then undergo full-body
      single-photon emission-computed tomography (SPECT) scan 4 hours after cell infusion and on
      day 2. The labeling and imaging process may be repeated after at least 1 course of anticancer
      treatment.

      Cellular uptake is measured by reader/visual interpretation, a semiquantitative grading
      system, and tumor-to-background uptake ratios.

      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">February 10, 2012</completion_date>
  <primary_completion_date type="Actual">February 10, 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of baseline indium In 111-labeled peripheral blood mononuclear cells (PBMCs) trafficking into tumors</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of baseline indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into tumors</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of PBMC and PMNL trafficking prior to vs after therapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular uptake of PBMCs and PMNLs as measured by reader/visual interpretation, semiquantitative grading system, and tumor-to-background uptake ratios</measure>
  </primary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Lymphoma</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radionuclide imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111-labeled autologous peripheral blood mononuclear cells</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111-labeled autologous polymorphonuclear leukocytes</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        community sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-Hodgkin's lymphoma

               -  Indolent or aggressive disease

               -  Planning to receive a new regimen or starting a regimen of cancer therapy

          -  At least one tumor lesion measurable in two dimensions as ≥ 1.5 cm by CT scan

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  Life expectancy ≥ 3 months

          -  No concurrent medical complications that would preclude study compliance

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

          -  At least 3 weeks since prior chemotherapy (except for nonmyelosuppressive treatments)

          -  At least 3 weeks since prior radiation therapy

          -  Concurrent rituximab allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Wiseman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael M. Graham, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holden Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

